Title

Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology

Journal

The Lancet Infectious Diseases, 21(12)

ISSN

1473-3099

Authors

Thompson, George R
Le, Thuy
Chindamporn, Ariya
et al.

Publication Date

2021-12-01

DOI

10.1016/s1473-3099(21)00191-2

Peer reviewed

HHS Public Access

Author manuscript

Lancet Infect Dis. Author manuscript; available in PMC 2022 September 07.

Published in final edited form as:

Lancet Infect Dis. 2021 December ; 21(12): e364–e374. doi:10.1016/S1473-3099(21)00191-2.

Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology

George R Thompson III,

Department of Internal Medicine, Division of Infectious Disease, UC Davis Medical Center, Sacramento, CA, USA

Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA

Thuy Le,

Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, NC, USA

Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

Correspondence to: Prof George R Thompson III, Department of Internal Medicine, Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA 95817, USA, grthompson@ucdavis.edu.

Contributors

GRT, TL, AC, and ACP served as guideline coordinators and served as the chair for each subsection working group. All authors contributed to the writing and editing of the manuscript.

Declaration of Interests

GRT received research funding from Amplyx Pharmaceuticals, Astellas, Basilea Pharmaceutica, Cidara Therapeutics, F2G, IMMY, Mayne Pharma, and Scynexis, and served as a consultant for Amplyx Pharmaceuticals, Astellas, Basilea Pharmaceutica, Cidara Therapeutics, F2G, IMMY, Mayne Pharma, Scynexis, and Pfizer. MJB is a founding partner and holds shares of Micología Molecular SL, she has received grant support from the Instituto de Salud Carlos III and has been paid for talks on behalf of United Medical LTDA. AA-I has received research grants to their institution from F2G and honoraria as a speaker from Gilead Sciences and Pfizer. DA-J holds share options in Pulmocide and has received grant support from Pulmocide, Astellas Pharma, Pfizer, and Gilead Sciences. He has received lecture honoraria from Astellas Pharma, Pfizer, Gilead Sciences, and AstraZeneca. JWB has served as a consultant for Pfizer. JFWC has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong, and was an invited speaker for Gilead Sciences Hong Kong and Luminex Corporation. OAC is funded by the German Federal Ministry of Education and Research, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy (CECAD, EXC 2030—390661388), and has received research grants from Actelion, Amplyx Pharmaceuticals, Astellas Pharma, Basilea Pharmaceutica, Cidara Therapeutics, Da Volterra, F2G, Gilead Sciences, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer, and, Scynexis. OAC is also a consultant to Actelion, Allecra Therapeutics, Amplyx Pharmaceuticals, Astellas, Basilea Pharmaceutica, Biosys UK, Cidara Therapeutics, Da Volterra, Entasis, F2G, Gilead Sciences, Matinas BioPharma, MedPace, Menarini Ricerche, Roche Diagnostics, Merck/MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, and Vical, and received lecture honoraria from Astellas, Basilea Pharmaceutica, Gilead Sciences, Grupo Biotoscana, Merck/MSD, and Pfizer. NK received honoraria from Astellas, Gilead Sciences, Merck/MSD, and Pfizer, and received grants from Merck/MSD and Pfizer. NK was a speaker for Astellas, Gilead Sciences, Merck/MSD, and Pfizer and an adviser for Gilead Sciences, Merck/MSD, and Pfizer. DCMK has sat on advisory boards for Becton Dickinson and Merck/MSD, and received financial and travel support unrelated to the current work from Merck/MSD. MHM has received research support and served as a consultant for Astellas and Scynexis. ISS has served as an adviser to Avir Pharma. AS has received grant funding from Astellas and has consulted for Scynexis, Minnetronix Medical, Mayne Pharma, and Viamet Pharmaceuticals. J-PG has received research grant support from Pfizer. FQ-T has received research grants from Astellas, Merck/MSD, and Pfizer, and also received payments for presentations and continued medical education from Merck/MSD, Pfizer, United Medical, and Teva Brazil. PEV reported grants from Gilead Sciences, Merck/MSD, Pfizer, F2G, and Thermo Fisher Scientific, and travel support from OLM Systems and IMMY, outside of the submitted work. ACP has received research grant support on behalf of Pfizer, Gilead Sciences, Merck/MSD, and IMMY. He has also given paid talks for Pfizer, United Medical, Gilead Sciences, Merck/MSD, Astellas, and IMMY, and participated on the medical board of Pfizer, United Medical, Gilead Sciences, and Merck/MSD. All other authors declare no competing interests.

See Online for appendix

Ariya Chindamporn,
Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Carol A Kauffman,
VA Ann Arbor Healthcare System, Ann Arbor, MI, USA

Department of Internal Medicine, Division of Infectious Diseases, University of Michigan, Ann Arbor, MI, USA

Ana Alastruey-Izquierdo,
Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

Neil M Ampel,
Division of Infectious Diseases, Mayo Clinic, Phoenix, AZ, USA

Department of Internal Medicine, Division of Infectious Diseases, University of Arizona College of Medicine, Tucson, AZ, USA

David R Andes,
Department of Internal Medicine, Division of Infectious Diseases, and Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, USA

Darius Armstrong-James,
Department of Infectious Diseases, Imperial College London, London, UK

Olusola Ayanlowo,
Department of Medicine, Faculty of Clinical Sciences, University of Lagos, Lagos, Nigeria

John W Baddley,
Department of Internal Medicine, Division of Infectious Disease, University of Maryland School of Medicine, Baltimore, MD, USA

Bridget M Barker,
Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA

Leila Lopes Bezerra,
Cellular Mycology and Proteomics Laboratory, Rio de Janeiro State University, Rio de Janeiro, Brazil

Maria J Buitrago,
Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

Leili Chamani-Tabriz,
Infectious Diseases Unit, Department of Internal Medicine, Saudi German Hospital Dubai, Dubai, UAE

Jasper F W Chan,
State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China

Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China

Methee Chayakulkeeree,
Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Oliver A Cornely,
Department of Internal Medicine, Excellence Center for Medical Mycology, University Hospital of Cologne, Cologne, Germany

Department of Internal Medicine, Division of Infectious Diseases, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany

Cao Cunwei,
Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Jean-Pierre Gangneux,
Department of Internal Medicine, Division of Infectious Diseases, Rennes University, CHU Rennes, Inserm, IRSET-UMR_S 1085, Rennes, France

Nelesh P Govender,
National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa

Department of Internal Medicine, Division of Infectious Diseases, University of the Witwatersrand, Johannesburg, South Africa

Ferry Hagen,
Westerdijk Fungal Biodiversity Institute, Utrecht, Netherlands

Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands

Laboratory of Medical Mycology, Jining No 1 People's Hospital, Jining, China

Mohammad T Hedayati,
Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Tobias M Hohl,
Infectious Disease Service, Department of Medicine; Memorial Sloan Kettering Cancer Center, New York, NY, USA

Immunology Program, Sloan Kettering Institute, New York, NY, USA

Grégory Jouvion,
Sorbonne Université, INSERM, Pathophysiology of Pediatric Genetic Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Armand-Trousseau, UF Génétique Moléculaire, Paris, France

Institut Pasteur, Experimental Neuropathology Unit, Paris, France

Chris Kenyon,

Institute of Tropical Medicine, Antwerp, Belgium

Christopher C Kibbler,
Centre for Medical Microbiology, University College London, London, UK

Nikolai Klimko,
Department of Clinical Mycology, Allergy, and Immunology, I Mechnikov North-Western State Medical University, St Petersburg, Russia

David C M Kong,
Pharmacy Department, Ballarat Health Services, Ballarat, VIC, Australia

National Centre for Antimicrobial Stewardship, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

Robert Krause,
Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Low Lee Lee,
Department of Internal Medicine, Hospital Sultanah Bayiyah, Alor Setar, Kedah, Malaysia

Graeme Meintjes,
Wellcome Centre for Infectious Diseases Research, University of Cape Town, Cape Town, South Africa

Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Department of Medicine, University of Cape Town, Cape Town, South Africa

Marisa H Miceli,
Department of Internal Medicine, Division of Infectious Diseases, University of Michigan, Ann Arbor, MI, USA

Peter-Michael Rath,
Institute of Medical Microbiology, University Hospital Essen, Essen, Germany

Andrej Spec,
Division of Infectious Disease, Washington University School of Medicine, St Louis, MO, USA

Flavio Queiroz-Telles,
Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil

Ebrahim Variava,
Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa

Paul E Verweij,
Department of Medical Microbiology, Excellence Center for Medical Mycology, Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, Netherlands

Ilan S Schwartz,

Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

Alessandro C Pasqualotto
Department of Clinical Medicine, Federal University of Health Sciences of Porto Alegre Porto Alegre, Brazil

Molecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil

Abstract

The global burden of the endemic mycoses (blastomycosis, coccidioidomycosis, emergomycosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis, and talaromycosis) continues to rise yearly and these infectious diseases remain a leading cause of patient morbidity and mortality worldwide. Management of the associated pathogens requires a thorough understanding of the epidemiology, risk factors, diagnostic methods and performance characteristics in different patient populations, and treatment options unique to each infection. Guidance on the management of these infections has the potential to improve prognosis. The recommendations outlined in this Review are part of the “One World, One Guideline” initiative of the European Confederation of Medical Mycology. Experts from 23 countries contributed to the development of these guidelines. The aim of this Review is to provide an up-to-date consensus and practical guidance in clinical decision making, by engaging physicians and scientists involved in various aspects of clinical management.

Introduction

The endemic mycoses are caused by a diverse group of fungi that share characteristics: each fungus occupies a specific ecological niche in the environment and is able to cause disease in healthy and immunocompromised hosts. There are numerous species of dimorphic fungi; however, *Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix* spp, and *Talaromyces marneffei* (formerly *Penicillium marneffei*) represent the most commonly encountered causes of infections in clinical care. Biosafety is an important consideration when handling these organisms, and laboratories should incorporate national guidance and regulations into their processes and practices to ensure the safety of laboratory staff. There are substantial differences in the geographical distribution, clinical presentation, radiographic manifestations, diagnostic approach, and therapeutic interventions among these mycoses. Management requires recognition of risk factors (eg, environmental exposure in an endemic region) and appropriate use of diagnostic and therapeutic interventions. Readily available guidance is important to ensure efficient diagnosis and treatment, and to optimise patient outcomes.

This Review contains comprehensive guidance to facilitate clinical decision making and to provide an overview of the areas of uncertainty in the field. We aim to address limitations of previous recommendations, by engaging physicians and scientists involved in various aspects of the endemic mycoses, representing the fields of dermatology, haematology, infectious diseases, intensive care, microbiology, paediatrics, pathology, pharmacology, radiology, and surgery. Additionally, the guideline group, which comprises experts from all parts of the world, updates current knowledge in the field via a strict methodology

consistent with a previous guideline document.[1] The evidence and a full description of the methodology and literature supporting each recommendation can be found in the appendix (pp 1–150). The general approach applied in the European Confederation of Medical Mycology guideline programme has been described previously.[1] We invited experts to participate in this specific guideline in February, 2018. Our selection of experts was determined by their publication activity in the field of the endemic mycoses, their personal involvement in patient management, and their distribution over the world regions defined by the UN as previously described.[1] Further information on guideline development, systematic approach, authors, and work flow is provided in the panel. 37 scientific societies focusing on infectious diseases reviewed and endorsed this guidance document (appendix p 149).

Blastomycosis

Epidemiology

Blastomyces spp have been isolated in soils near freshwater drainage systems, although wind probably has a role in dispersal.[2] *Blastomyces dermatitidis* and *Blastomyces gilchristii* are seen primarily in southeastern and southcentral regions of the USA bordering the Mississippi and Ohio River basins, the northcentral states bordering the Great Lakes, and areas surrounding the St Lawrence Seaway, extending from Quebec into Saskatchewan in Canada (figure 1A). Other species are found in western parts of Canada and the USA (*Blastomyces helicus*),[3] in Africa and the Middle East (*Blastomyces percursus*), and in South Africa (*Blastomyces emzantsi*).

Diagnosis

The typical appearance of *Blastomyces* spp on microscopic examination of patient samples is a round-to-oval multinucleate yeast cell, 8–15 μm in size, with a single broad-based bud (figure 2A). Septate hyphae with a diameter of 1–2 μm and oval single-cell conidia at the tip of conidiophores (lollipop-like shape) are characteristic but not specific.[4] Serological methods do not have the specificity necessary for diagnosis. An antigen detection assay (MiraVista, Indianapolis, IN, USA) is available with a reported sensitivity of 85–93% and a specificity of 79–99%, although this assay has not been validated for less common *Blastomyces* spp. Urine testing is more sensitive than serum or bronchoalveolar lavage.[5]

Treatment

Antifungal therapy is recommended for all forms of blastomycosis. The severity of patient illness and the underlying level of immunosuppression guide these treatment choices. For patients with severe disease, liposomal amphotericin B (L-AmB; 5 mg/kg per day) or an alternative amphotericin B (AmB) formulation is generally recommended. The availability of the triazole agents has shortened the required duration of AmB therapy to 1–2 weeks for many patients. After clinical improvement with AmB, stepdown to a triazole is recommended. The triazole component is most often continued for 6–12 months depending on the site of disease, with more prolonged courses recommended for CNS or bone involvement, based on relapses in case series.[6]

The most used triazole-based treatment is itraconazole (200–400 mg/day), which is recommended as the first-line triazole, based on success rates of 90–95% in a prospective phase 2 study.[7] A small trial with fluconazole of 23 patients was less successful than previous reports of itraconazole,[8] but efficacy with a higher dose of fluconazole (400–800 mg/day) therapy was moderately successful (87%) and can be used in patients who are intolerant to other triazoles.[9] A case series where voriconazole was used has shown outcomes similar to itraconazole, including favourable efficacy in disease of the CNS.[10] Case reports with posaconazole and, more recently, isavuconazole suggest efficacy, although there is little experience with these agents.[11,12] The management of blastomycosis-associated acute respiratory distress syndrome is difficult and guided by data from case reports and small series of fewer than 50 cases. L-AmB is the mainstay of management. Corticosteroids have been used regularly for this indication in some centres, but there is little evidence for efficacy and expert consensus is absent.[13]

Recommendations

Clinical specimens should be examined microscopically with an optical brightener or fungal stains, or both. Fungal culture on Sabouraud dextrose agar or potato dextrose agar with and without cycloheximide should be incubated for up to 6 weeks at 25–30°C. In the USA and Canada, a *Blastomyces* antigen assay showing an acceptable sensitivity and specificity (>80%) is available. Testing of urine is preferred over other sample types. All patients with blastomycosis should have a chest radiograph done. Additional imaging is based on symptoms, to ascertain if complications of the disease have occurred and to determine a response to therapy.

All patients with blastomycosis should be treated. Patients with severe disease should receive L-AmB induction therapy in most cases. Alternative AmB formulations are acceptable if L-AmB is not available. After clinical improvement with AmB, stepdown to itraconazole is recommended for 6–12 months. Longer courses of therapy are recommended for individuals with CNS or bone involvement. Alternative triazoles can be used in cases of itraconazole intolerance, although higher doses of fluconazole are required and evidence with other triazoles is scarce.

Coccidioidomycosis

Epidemiology

Coccidioidomycosis is caused by *Coccidioides immitis* and *Coccidioides posadasii*. These fungi survive well in areas of low precipitation (12–50 cm of rainfall per year), with few winter freezes and alkaline soil.[14] The inoculum needed for infection is small and can be as low as a single arthroconidium. *C immitis* is primarily found in California and Washington in the USA and in northwest Mexico, whereas *C posadasii* is found in the southwestern region of the USA, in Mexico, and in arid regions of South America (figure 1B).[15] Within the USA, the number of coccidioidomycosis cases continues to increase yearly.

Diagnosis

The diagnosis of coccidioidomycosis is proven by culture of *Coccidioides* spp from any clinical site. Histopathology can show spherules or endospores (figure 2B). *Coccidioides* spp grow on routine blood agar and Sabouraud dextrose agar, incubated at 25–30°C. Mycelial growth can be seen as early as 4–5 days after incubation, although cultures should be held for up to 6 weeks. Most patients are diagnosed with coccidioidomycosis via serological testing. EIA, immunodiffusion, and complement fixation (CF) testing are commercially available and exhibit differing sensitivity and specificity.[16] A typical coccidioidal infection results in serum IgM production within 1–3 weeks of symptoms onset, followed thereafter (4–8 weeks) by IgG production.[17] Coccidioidal antigen testing is also available with an EIA and might be helpful in patients who are highly immunocompromised. Meningitis remains a particularly morbid form of the disease and should be considered with sustained headache or other CNS symptoms.[18]

Patients with primary pulmonary disease usually have a dense infiltrate, often in the upper lobe, with associated hilar or mediastinal adenopathy. Severe manifestations of acute pulmonary coccidioidomycosis are uncommon and are most frequently observed after a high inoculum exposure or substantial underlying immunodeficiency.

Treatment

Many clinicians support a period of observation rather than antifungal therapy for individuals with primary pulmonary coccidioidomycosis because most patients will control their infection without long-term sequelae. Two observational studies have shown antifungal therapy does not appear to affect the risk of extrapulmonary dissemination.[19,20] Treatment with fluconazole or itraconazole should be given to all patients with underlying immunosuppression, substantial cardiopulmonary comorbidities, or those with prolonged infection or CF titres of 1/32 or higher. Patients exhibiting weight loss of more than 10%, night sweats for more than 3 weeks, and infiltrates exceeding 50% of one lung or bilateral disease should be treated as well, particularly if these individuals have CF titres of 1/32 or higher.[21] Severe disease should be treated with an AmB formulation, followed by a triazole. Disease refractory to fluconazole is treated with itraconazole, voriconazole, posaconazole, or AmB, depending on disease severity.[21,22]

Recommendations

We recommend that clinical specimens be examined microscopically with standard fungal stains for the presence of *Coccidioides* spp. Identification of spherules in a clinical specimen is considered proven disease, even in the absence of positive culture results. We recommend serological testing of blood in all patients with suspected coccidioidomycosis, with repeat quantitative serological testing (CF) approximately every 12 weeks during care to evaluate a response to therapy. A CSF sample should be obtained from all patients suspected of meningitis. All patients with coccidioidomycosis should have a chest radiograph. Pulmonary infiltrates from *Coccidioides* spp should be followed up to resolution, with repeat imaging after the initial infection. Treatment for pulmonary disease should start with fluconazole or itraconazole, whereas meningitis should be treated with fluconazole as the first-line agent.

Emergomycosis

Epidemiology

There are currently five species of *Emergomyces* reported to cause human disease. Nearly all cases of emergomycosis have involved patients who were immunocompromised. Disease caused by *Emergomyces pasteurianus* has been reported in patients from Europe, Asia, India, and Africa. *Emergomyces africanus* has been reported only from southern Africa (figure 1C). Emergomycosis is the most frequently diagnosed endemic mycosis in South Africa.[23] Emergomycosis caused by *Emergomyces canadensis* has been infrequently reported in central and western regions of North America, whereas *Emergomyces orientalis* and *Emergomyces europaeus* have been reported from only a single patient each.[24,25]

Diagnosis

The diagnosis of emergomycosis is proven by culture of *Emergomyces* spp from blood or tissue.[26,27] Clinical samples inoculated onto standard fungal media (eg, Sabouraud agar, malt extract agar, or potato dextrose agar) are incubated at 24–30°C and typically grow after 7–30 days. The identification of *Emergomyces* spp in culture can be confirmed by DNA sequencing.[26] Skin lesions are present at the time of diagnosis in 95% of patients and biopsy is essential for diagnosis.[26] Histopathology is suggestive, but *Emergomyces* spp yeast cells are morphologically indistinguishable from those of *Histoplasma* spp. Antigen testing specific for emergomycosis is not available.

Treatment

There have been no trials regarding the treatment of emergomycosis, and all data are observational. Minimum inhibitory concentrations for fluconazole of 64 μg/mL or more have been reported for most isolates tested, including isolates of *E africanus*, *E canadensis*, *E orientalis*, and *E pasteurianus*.[28] AmB and mould-active triazoles have been consistently active in vitro. The optimal dose and duration of antifungal therapy for emergomycosis is not yet established. Most patients reported in the literature have been treated either with AmB followed by itraconazole or itraconazole alone.[29]

Recommendations

Culture of *Emergomyces* spp from a patient with compatible symptoms should be considered diagnostic of disease. When skin lesions are present, punch or incisional biopsies are strongly recommended; blood cultures should be done in aerobic bottles and, where available, lysis-centrifugation tubes. Patients who are immunocompromised with disseminated disease should be treated with L-AmB (3–5 mg/kg per day) for 10–14 days or with an alternative AmB formulation. Maintenance treatment with itraconazole (200 mg orally twice daily) is recommended for 12 months pending immune reconstitution.

Histoplasmosis

Epidemiology

Histoplasma spp are commonly present in soil contaminated with bat guano and bird excreta. Studies of skin testing with histoplasmin have shown that millions of people living

in Latin America and the Caribbean have been exposed to the fungus.[30] In North America, histoplasmosis is highly endemic along the St Lawrence, Mississippi, and Ohio River basins, and microfoci exist in the mid-eastern states (figure 1D). Although histoplasmosis is most frequently documented in the Americas, this condition is a true global disease. In a 5-year European study, 118 cases of histoplasmosis were reported,[31] with autochthonous cases reported in Germany, Italy, and Turkey. In Africa, over 400 cases of histoplasmosis have been reported,[32] with most cases secondary to *Histoplasma capsulatum* var *duboisii* in west Africa.

Diagnosis

All biopsied tissues should be submitted for either periodic acid–Schiff or Grocott methenamine silver staining (figure 2C). The sensitivity of tissue examination varies by the burden of disease and is highly dependent on the degree of host immunosuppression.[33] Conventional blood cultures have low sensitivity (around 50%) in patients with advanced HIV,[34] although improved sensitivity is seen with the lysis-centrifugation method. Serological testing is most useful for patients with chronic pulmonary histoplasmosis and might not be useful in patients with severe immunosuppression. The detection of *Histoplasma* spp antigen in urine or serum is useful in making a rapid diagnosis of probable histoplasmosis and, if positive, is useful for longitudinal assessment. Chest, abdominal, and CNS imaging should be done according to the clinical scenario.

Treatment

In a randomised clinical trial, L-AmB at 3 mg/kg daily was shown to provide a survival benefit, compared with AmB-deoxycholate (AmB-d), in patients with advanced HIV and disseminated histoplasmosis.[35] After successful induction therapy during the treatment of disseminated infection, itraconazole (200 mg twice daily) is usually given for at least 1 year.[36] In individuals with less severe disease, fluconazole has a lower success rate than itraconazole,[35,37] and emergence of fluconazole resistance has been reported in patients receiving fluconazole therapy.[38] Voriconazole is not routinely recommended.[39] Histoplasmosis secondary to tumour necrosis factor-α inhibitor therapy requires discontinuation of the tumour necrosis factor-α blocker during antifungal therapy. After a clinical response to treatment, pharmacological immunosuppression might be reinstituted if antifungal treatment is administered for around 12 months and the test results for the individuals are negative for *Histoplasma* spp antigen.[40]

Recommendations

Whenever possible, tissue should be obtained for the histopathological diagnosis of histoplasmosis, using fungal stains (ie, Grocott methenamine silver staining) and fungal culture. Most clinical laboratories identify isolates using a DNA probe, although in some locations the conversion from mycelial phase to yeast is still done. L-AmB is the drug of choice for induction therapy for patients with advanced HIV and moderate-to-severe histoplasmosis. Other AmB formulations are acceptable alternatives when L-AmB is not available. Itraconazole is an alternative induction therapy for patients with less severe infection. Antifungal treatment in non-immunosuppressed patients is suggested for at least 6

months, although the severity and site of disease need to be considered before determining the duration of therapy.

Paracoccidioidomycosis

Epidemiology

Paracoccidioides spp are soil-inhabiting fungi, although the current understanding of their precise environmental habitat is limited. The primary infection usually occurs during the first two decades of life in individuals who live within the endemic regions of Latin America and who have diverse activities related to the management of soil or soil products. Paracoccidioidomycosis occurs in the subtropical humid areas of most of the countries in Latin America (figure 1E). The prevalence of this infection is known to vary greatly between different endemic regions. However, skin testing has shown up to 50–75% of individuals within an endemic region have been infected.[41] The acute or subacute clinical forms, representing 10% of the clinical cases, are prevalent in children and adolescents (younger than 16 years), affecting both sexes equally. The chronic form is prevalent in adults (older than 16 years), with a male to female ratio of 20:1, and this difference might be secondary to inhibition of mycelial-to-yeast conversion by oestrogens.[42]

Diagnosis

Microscopy enables a proven diagnosis of paracoccidioidomycosis to be made. Rounded, thick-walled yeast cells (typically 15–30 μm in diameter, and up to 60 μm in some cases) with multiple buds (ship wheel-like, pilot wheel-like, or Mickey Mouse ear-like cells; figure 2D) are diagnostic features and are frequently observed in aspirates but are uncommon in sputum samples. Cultures should be inoculated and incubated at 25–30°C for 4–8 weeks, although these cultures might be negative depending on the site and burden of infection. Most patients are diagnosed using non-invasive testing, such as serological testing. Immunodiffusion assays (IMMY, Norman, OK, USA) are the most widely used reference assay.[43–45] This assay is inexpensive and has a high specificity (>95%) and sensitivity (around 80%), although the assay might not be widely available in all countries. Quantitative antibody titres are higher in patients with acute and more severe disease forms than in patients with less severe disease. The guidelines for the use of antibody detection in the diagnosis of paracoccidioidomycosis have been summarised in the appendix (p 72). Serological testing can also be used to assess the response to treatment, with a decrease in titre considered as a favourable sign.[43] Antigen detection assays are not yet commercially available.

Treatment

Itraconazole has largely been used for patients with mild-to-moderate clinical forms of the disease (appendix pp 77–78).[46–48] In a single-centre noncomparative study, itraconazole has been shown to exhibit an efficacy rate of 91% (median of 6 months for the duration of treatment).[47] Comparison of itraconazole with co-trimoxazole (trimethoprim–sulfamethoxazole) has shown itraconazole to be superior (86·4% success rate *vs* 51·3% success rate).[49] Another study showed a significantly shorter time to serological cure in the itraconazole group compared with the co-trimoxazole group (105 days *vs* 159 days;

p=0.001).[48] Voriconazole (6 mg/kg per day for 6–12 months) is similarly efficacious in paracoccidioidomycosis and is useful in cases with CNS involvement.[46] AmB is recommended for patients who are immunocompromised (ie, patients with advanced HIV disease). After induction therapy with an AmB formulation, maintenance treatment with an azole derivative or co-trimoxazole is required.

Recommendations

Due to the characteristic appearances of *Paracoccidioides* spp in clinical samples, microscopy has an important role in the diagnosis of paracoccidioidomycosis. Microscopy should preferably be done using optical brighteners. Paracoccidioidomycosis is mainly a chronic condition, and antibodies can be detected in most infected patients. However, the accuracy of serological assays for the diagnosis of paracoccidioidomycosis is dependent on the quality as well as the sensitivity and specificity of the antigen preparation used. It is recommended that serological testing only be done by reference laboratories, using reagents with known and published performance characteristics. Itraconazole (200 mg daily for 9–12 months) is the therapy of choice for patients with mild-to-moderate forms of paracoccidioidomycosis, with co-trimoxazole (for 18–24 months) being the main therapeutic alternative to itraconazole. A short (2–4 weeks) induction therapy with AmB is reserved for severe cases, or for patients who are immunocompromised. Induction therapy with AmB should be followed by 200–400 mg of itraconazole.

Sporotrichosis

Epidemiology

Sporotrichosis is a subacute-to-chronic infection caused by the dimorphic saprotrophic fungal genus *Sporothrix*, of which only a few species are known to infect humans and animals.[50] The estimated prevalence of sporotrichosis is between 0·1–0·5%, although the number of cases is rapidly increasing in Brazil, which specifically relates to *Sporothrix brasiliensis* zoonotic transmission (figure 1F). Previously, it was believed that only members of the pathogenic clade of *Sporothrix schenckii* were able to cause disease, but a taxonomic revision has shown the presence of novel medically relevant species: *S brasiliensis*, *Sporothrix globosa, Sporothrix mexicana*, and *Sporothrix pallida*.[51,52] The clinical presentation of *S schenckii* infection is typically a chronic subcutaneous mycosis. *S globosa* most commonly causes a fixed or lymphocutaneous infection, whereas infections caused by *S brasiliensis* are often more severe. Infections caused by *S mexicana* or *S pallida* typically present with subcutaneous nodules or draining lesions.[50]

Diagnosis

The standard and most sensitive method for diagnosis of invasive sporotrichosis is culture, although cultures might be negative.[53] Material obtained via lesion aspiration, biopsy, sputum, or body fluids should be inoculated on Sabouraud dextrose agar and incubated at room temperature (figure 2E). Histopathology is often negative, even with the use of fungal specific stains, which is largely due to the small number of organisms that are needed to cause disease. The ovoid yeast cells are 3–5 μm in diameter, oval-shaped to cigar-shaped, and eosinophilic projections from the yeast can be present, representing the asteroid body

associated with *Sporothrix* spp. A latex agglutination assay has been used in the past to assist in the diagnosis of meningeal sporotrichosis,[54] but this assay is no longer available, and serological testing has little use in anything other than meningitis. Other assays have been developed and have exhibited excellent sensitivity (89–90%) and specificity (100%) but are currently limited by availability.[53–55]

Treatment

For cutaneous and lymphocutaneous sporotrichosis, therapy with itraconazole is associated with response rates of 80–100% (appendix pp 87–89).[56–58] A variety of different itraconazole doses have been studied, with no clear difference observed among doses prescribed.[56] In a cohort study comparing terbinafine (250 mg daily) and itraconazole (100 mg daily), there was no marked difference in outcomes and no marked difference in adverse events between groups.[58] Saturated solution of potassium iodide has long been used for the treatment of cutaneous sporotrichosis, with response rates between 70% and 89%.[59,60] Although this option is efficacious and cost-effective, alternative agents are preferred due to the difficulty of this regimen for patients (eg, dysgeusia, gastrointestinal intolerance, and acneiform eruptions).[59] Insufficient data are available for newer azole agents used in single or combination salvage therapy, and high minimum inhibitory concentrations have been observed in vitro with voriconazole and isavuconazole, suggesting these agents are not effective.[61]

Recommendations

We recommend culture and histopathological evaluation of skin or tissue aspirates or biopsies when the diagnosis of sporotrichosis is considered. Skin and soft tissue sporotrichosis rarely warrants imaging and, in these cases, only if concern exists for spread to contiguous bone or deeper structures. For cutaneous and lymphocutaneous sporotrichosis, itraconazole (200 mg orally daily) is recommended for 2–4 weeks after resolution of lesions, usually for a 3-month to 6-month duration of therapy. Alternative therapies include terbinafine (500 mg orally twice daily), or increasing the oral itraconazole dose to 200 mg twice daily. We recommend against using voriconazole or isavuconazole. For disseminated or severe pulmonary sporotrichosis, L-AmB (3–5 mg/kg daily) is recommended or, alternatively, AmB-d (0·7–1·0 mg/kg daily). After the patient has shown a favourable response to treatment, therapy can be changed to itraconazole (200 mg orally twice daily) for at least 12 months.

Talaromycosis

Epidemiology

Talaromycosis is an invasive fungal infection caused by the thermally dimorphic fungus *T marneffei* and is endemic throughout southeast Asia and is highly endemic in northern Thailand, Vietnam, Myanmar, Hong Kong, Taiwan, southern China, and northeastern India (figure 1G).[62] HIV is a major risk factor for talaromycosis. In just over two decades, the HIV epidemic has transformed talaromycosis from a rare infection to a leading HIV-associated opportunistic infection in southeast Asia, accounting for up to 16% of HIV-associated hospital admissions.[63–65] Furthermore, the fungus is the second leading cause

of HIV-associated bloodstream infections and death in Vietnam and southern China, with a mortality of up to 28%.[66]

Diagnosis

A presumptive diagnosis of talaromycosis is made based on the microscopic examination of skin lesion scrapings, lymph node or bone marrow aspirates, or based on the histopathological examination of tissue sections. Occasionally, *T marneffei* can be observed on the peripheral blood smear of patients with fungaemia. Characteristics of *T marneffei* include identification of a transverse septum in a dividing yeast cell (figure 2F), 3–6 μm in diameter, round-to-oval in shape, extracellular, and present within macrophages. Antigen detection (Mp1p) is highly accurate, inexpensive, does not require sophisticated equipment, and is particularly well suited for patients with advanced HIV disease and high fungal burden in the blood. A commercial antigen detection assay was approved in 2018 in China for clinical use and other assays are in development. A number of qPCR assays, based on specific *T marneffei* regions, have been developed. These assays have high specificities (100%) in whole blood or plasma samples, but sensitivity ranges from 70% to 86%.[67,68]

Treatment

Disseminated talaromycosis is fatal if untreated, and the mortality rate approaches 30% even with antifungal therapy.[62,65,66] Treatment should be given promptly to all patients who are immunocompromised. Similar to the approach in cryptococcosis, antifungal therapy is divided into induction, consolidation, and maintenance phases. In a multicentre, randomised controlled trial in Vietnam, induction therapy with AmB-d was shown to be superior to itraconazole with respect to mortality, blood fungal clearance, disease relapse, and immune reconstitution inflammatory syndrome.[69] A double-blind, placebo-controlled trial in Thailand showed that maintenance therapy with itraconazole (200 mg daily) in patients with advanced HIV disease decreased the relapse rate from 57% to 0% ($p<0{\cdot}001$).[70] Primary prophylaxis with itraconazole (200 mg orally daily) has been shown to reduce the incidence of invasive fungal infections (ie, talaromycosis, cryptococcosis, and oesophageal candidiasis) in HIV-infected patients with a CD4 count of less than 200 cells per μL in a randomised controlled trial in Thailand.[71]

Recommendations

In patients with a clinical suspicion of talaromycosis, we strongly recommend that patient specimens, including skin smears or biopsy, blood, sputum, and aspiration samples of lymph nodes, pus, bone marrow, pleural fluid, ascites, and CSF, should be sent for direct microscopy and fungal cultures. Identification of a transverse septum on microscopy establishes a presumptive diagnosis. Culture is the gold standard for diagnosis of talaromycosis and should be observed for up to 14 days. In settings where the Mp1p test is not available but there is a high clinical suspicion in patients without typical skin lesions, we recommend qPCR testing of whole blood or plasma with a validated in-house assay as a rapid diagnostic. We strongly recommend induction therapy with AmB. Specifically, L-AmB is preferred over AmB-d where available. L-AmB is given at 3–5 mg/kg per day intravenously, and AmB-d is given at 0·7 mg/kg per day intravenously, both for 10–14 days,

followed by consolidation therapy with itraconazole (200 mg orally twice daily) for 10 weeks, followed by maintenance therapy with itraconazole (200 mg orally daily).

Future directions and unmet needs

Important questions persist in the field of the endemic mycoses. The fungal kingdom has undergone substantial taxonomic revision and new species have recently been proposed. The importance of these cryptic species has yet to be determined, although emerging data suggest antifungal susceptibility and host differences. In addition to cryptic species (which are distinguished only by genetic but not phenotypic differences), several morphologically and clinically distinct fungi, such as *S brasiliensis*, several new species of *Blastomyces*, and the new genus *Emergomyces* have been recognised. New diagnostics focused on non-invasive methods (eg, serological testing, antigen capture, breath testing, and imaging) are also under active investigation and merit further study. Invitro susceptiblity testing and its correlation to clinical response will also need to be further evaluated. Because many diagnostics require the expertise of specialised reference laboratories, improvements in this area would be a welcome advance and might reduce the time to diagnosis and initiation of treatment. A number of novel antifungal agents are in various stages of development, and several have substantial activity in the treatment of endemic mycoses and might be able to alter the time course of disease.[72,73] Improvements in our understanding of these diverse mycoses require the input and collaboration of a wide range of investigators, and through collaborative efforts advanced the field of endemic mycoses can continue.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank Kerstin Albus and Susann Blossfeld for technical support they provided during the development of this manuscript. We would like to also thank Dr Martin Hoenigl for his assistance during the guideline process.

References

1. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19: e405–21. [PubMed: 31699664]
2. McTaggart LR, Brown EM, Richardson SE. Phylogeographic analysis of *Blastomyces dermatitidis* and *Blastomyces gilchristii* reveals an association with North American freshwater drainage basins. PLoS One 2016; 11: e0159396. [PubMed: 27428521]
3. Schwartz IS, Wiederhold NP, Hanson KE, Patterson TF, Sigler L. *Blastomyces helicus*, a new dimorphic fungus causing fatal pulmonary and systemic disease in humans and animals in western Canada and the United States. Clin Infect Dis 2019; 68: 188–95. [PubMed: 29878145]
4. Patel AJ, Gattuso P, Reddy VB. Diagnosis of blastomycosis in surgical pathology and cytopathology: correlation with microbiologic culture. Am J Surg Pathol 2010; 34: 256–61. [PubMed: 20090507]

5. Bariola JR, Hage CA, Durkin M, et al. Detection of *Blastomyces dermatitidis* antigen in patients with newly diagnosed blastomycosis. Diagn Microbiol Infect Dis 2011; 69: 187–91. [PubMed: 21251563]
6. Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin Infect Dis 2000; 30: 969–71. [PubMed: 10880319]
7. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489–97. [PubMed: 1332471]
8. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995; 20: 267–71. [PubMed: 7742428]
9. Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher doses of fluconazole. Clin Infect Dis 1997; 25: 200–05. [PubMed: 9332510]
10. Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40: e69–71. [PubMed: 15825017]
11. Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis 2016; 63: 356–62. [PubMed: 27169478]
12. Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother 2012; 56: 4029. [PubMed: 22564845]
13. Schwartz IS, Embil JM, Sharma A, Goulet S, Light RB. Management and outcomes of acute respiratory distress syndrome caused by blastomycosis: a retrospective case series. Medicine (Baltimore) 2016; 95: e3538. [PubMed: 27149459]
14. Stockamp NW, Thompson GR 3rd. Coccidioidomycosis. Infect Dis Clin North Am 2016; 30: 229–46. [PubMed: 26739609]
15. Brown J, Benedict K, Park BJ, Thompson GR 3rd. Coccidioidomycosis: epidemiology. Clin Epidemiol 2013; 5: 185–97. [PubMed: 23843703]
16. Van Dyke MCC, Thompson GR 3rd, Galgiani JN, Barker BM. The rise of *Coccidioides*: forces against the dust devil unleashed. Front Immunol 2019; 10: 2188. [PubMed: 31572393]
17. McHardy IH, Dinh BN, Waldman S, et al. Coccidioidomycosis complement fixation titer trends in the age of antifungals. J Clin Microbiol 2018; 56: 56.
18. Thompson G 3rd, Wang S, Bercovitch R, et al. Routine CSF analysis in coccidioidomycosis is not required. PLoS One 2013; 8: e64249. [PubMed: 23717579]
19. Blair JE, Chang YH, Cheng MR, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis 2014; 20: 983–90. [PubMed: 24865953]
20. Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis 2009; 48: 172–78. [PubMed: 19072555]
21. Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 2016; 63: e112–46. [PubMed: 27470238]
22. Thompson GR 3rd, Lewis JS 2nd, Nix DE, Patterson TF. Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis. Med Mycol 2019; 57 (suppl 1): S76–84. [PubMed: 30690601]
23. Maphanga TG, Birkhead M, Muñoz JF, et al. Human blastomycosis in South Africa caused by *Blastomyces percursus* and *Blastomyces emzantsi* sp. nov., 1967 to 2014. J Clin Microbiol 2020; 58: 58.
24. Wang P, Kenyon C, de Hoog S, et al. A novel dimorphic pathogen, Emergomyces orientalis (Onygenales), agent of disseminated infection. Mycoses 2017; 60: 310–19. [PubMed: 28240390]
25. Wellinghausen N, Kern WV, Haase G, et al. Chronic granulomatous lung infection caused by the dimorphic fungus *Emmonsia* sp. Int J Med Microbiol 2003; 293: 441–45. [PubMed: 14760976]
26. Kenyon C, Bonorchis K, Corcoran C, et al. A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 2013; 369: 1416–24. [PubMed: 24106934]
27. Schwartz IS, Govender NP, Corcoran C, et al. Clinical characteristics, diagnosis, management, and outcomes of disseminated emmonsiosis: a retrospective case series. Clin Infect Dis 2015; 61: 1004–12. [PubMed: 26060283]

28. Dukik K, Al-Hatmi AMS, Curfs-Breuker I, Faro D, de Hoog S, Meis JF. Antifungal susceptibility of emerging dimorphic pathogens in the family Ajellomycetaceae. Antimicrob Agents Chemother 2017; 62: 62.
29. Schwartz IS, Kenyon C, Lehloenya R, et al. AIDS-related endemic mycoses in Western Cape, South Africa, and clinical mimics: a cross-sectional study of adults with advanced HIV and recent-onset, widespread skin lesions. Open Forum Infect Dis 2017; 4: ofx186. [PubMed: 29164168]
30. Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T, Pasqualotto AC. Neglected endemic mycoses. Lancet Infect Dis 2017; 17: e367–77. [PubMed: 28774696]
31. Ashbee HR, Evans EG, Viviani MA, et al. Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group. Med Mycol 2008; 46: 57–65. [PubMed: 17885939]
32. Oladele RO, Ayanlowo OO, Richardson MD, Denning DW. Histoplasmosis in Africa: an emerging or a neglected disease? PLoS Negl Trop Dis 2018; 12: e0006046. [PubMed: 29346384]
33. Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53: 448–54. [PubMed: 21810734]
34. Dantas KC, Freitas RS, da Silva MV, Criado PR, Luiz ODC, Vicentini AP. Comparison of diagnostic methods to detect *Histoplasma capsulatum* in serum and blood samples from AIDS patients. PLoS One 2018; 13: e0190408. [PubMed: 29342162]
35. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137: 105–09. [PubMed: 12118965]
36. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807–25. [PubMed: 17806045]
37. McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996; 23: 996–1001. [PubMed: 8922792]
38. Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33: 1910–13. [PubMed: 11692303]
39. Hendrix MJ, Larson L, Rauseo AM, et al. Voriconazole versus Itraconazole for the initial and step-down treatment of histoplasmosis: a retrospective cohort. Clin Infect Dis 2020; published online Oct 28. 10.1093/cid/ciaa1555.
40. Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis 2015; 61: 409–17. [PubMed: 25870331]
41. Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6: 251–62. [PubMed: 18380607]
42. Blotta MH, Mamoni RL, Oliveira SJ, et al. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med Hyg 1999; 61: 390–94. [PubMed: 10497977]
43. Shikanai-Yasuda MA, Telles Filho FQ, Mendes RP, Colombo AL, Moretti ML. Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop 2006; 39: 297–310 (in Portuguese). [PubMed: 16906260]
44. Perenha-Viana MC, Gonzales IA, Brockelt SR, Machado LN, Svidzinski TI. Serological diagnosis of paracoccidioidomycosis through a western blot technique. Clin Vaccine Immunol 2012; 19: 616–19. [PubMed: 22301695]
45. de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165: 289–302. [PubMed: 18777635]
46. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai-Yasuda MA. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45: 1462–69. [PubMed: 17990229]
47. Naranjo MS, Trujillo M, Munera MI, Restrepo P, Gomez I, Restrepo A. Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol 1990; 28: 67–76. [PubMed: 2163442]

48. Cavalcante RS, Sylvestre TF, Levorato AD, de Carvalho LR, Mendes RP. Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidiodomycosis. PLoS Negl Trop Dis 2014; 8: e2793. [PubMed: 24743230]
49. Borges SR, Silva GM, Chambela MC, et al. Itraconazole *vs.* trimethoprim-sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis. Med Mycol 2014; 52: 303–10. [PubMed: 24577007]
50. Lopes-Bezerra LM, Mora-Montes HM, Zhang Y, et al. Sporotrichosis between 1898 and 2017: the evolution of knowledge on a changeable disease and on emerging etiological agents. Med Mycol 2018; 56 (suppl 1): 126–43. [PubMed: 29538731]
51. de Meyer EM, de Beer ZW, Summerbell RC, et al. Taxonomy and phylogeny of new wood- and soil-inhabiting *Sporothrix* species in the *Ophiostoma stenoceras-Sporothrix schenckii* complex. Mycologia 2008; 100: 647–61. [PubMed: 18833758]
52. Rodrigues AM, Della Terra PP, Gremião ID, Pereira SA, Orofino-Costa R, de Camargo ZP. The threat of emerging and re-emerging pathogenic *Sporothrix* species. Mycopathologia 2020; 185: 813–42. [PubMed: 32052359]
53. Barros MB, de Almeida Paes R, Schubach AO. *Sporothrix schenckii* and sporotrichosis. Clin Microbiol Rev 2011; 24: 633–54. [PubMed: 21976602]
54. Scott EN, Kaufman L, Brown AC, Muchmore HG. Serologic studies in the diagnosis and management of meningitis due to *Sporothrix schenckii*. N Engl J Med 1987; 317: 935–40. [PubMed: 3306388]
55. Bernardes-Engemann AR, Costa RC, Miguens BR, et al. Development of an enzyme-linked immunosorbent assay for the serodiagnosis of several clinical forms of sporotrichosis. Med Mycol 2005; 43: 487–93. [PubMed: 16320492]
56. de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, Martins EB, Teixeira JL, Wanke B. Treatment of cutaneous sporotrichosis with itraconazole—study of 645 patients. Clin Infect Dis 2011; 52: e200–06. [PubMed: 21628477]
57. Conti Díaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153–56. [PubMed: 1335550]
58. Francesconi G, Francesconi do Valle AC, Passos SL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia 2011; 171: 349–54. [PubMed: 21103938]
59. Macedo PM, Lopes-Bezerra LM, Bernardes-Engemann AR, Orofino-Costa R. New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients. J Eur Acad Dermatol Venereol 2015; 29: 719–24. [PubMed: 25229626]
60. Cabezas C, Bustamante B, Holgado W, Begue RE. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr Infect Dis J 1996; 15: 352–54. [PubMed: 8866807]
61. Paixão AG, Galhardo MCG, Almeida-Paes R, et al. The difficult management of disseminated *Sporothrix brasiliensis* in a patient with advanced AIDS. AIDS Res Ther 2015; 12: 16. [PubMed: 25949269]
62. Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis 2017; 17: e334–43. [PubMed: 28774701]
63. Sirisanthana T, Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis 1998; 3: 48–53. [PubMed: 9831676]
64. Hu Y, Zhang J, Li X, et al. *Penicillium marneffei* infection: an emerging disease in mainland China. Mycopathologia 2013; 175: 57–67. [PubMed: 22983901]
65. Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated *Penicillium marneffei* infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis 2011; 52: 945–52. [PubMed: 21427403]
66. Jiang J, Meng S, Huang S, et al. Effects of *Talaromyces marneffei* infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin Microbiol Infect 2019; 25: 233–41. [PubMed: 29698815]
67. Hien HTA, Thanh TT, Thu NTM, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma. Mycoses 2016; 59: 773–80. [PubMed: 27453379]

68. Li X, Zheng Y, Wu F, et al. Evaluation of quantitative real-time PCR and Platelia galactomannan assays for the diagnosis of disseminated *Talaromyces marneffei* infection. Med Mycol 2020; 58: 181–86. [PubMed: 31131856]

69. Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med 2017; 376: 2329–40. [PubMed: 28614691]

70. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of *Penicillium marneffei* infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339: 1739–43. [PubMed: 9845708]

71. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34: 277–84. [PubMed: 11740718]

72. Gintjee TJ, Donnelley MA, Thompson GR 3rd. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel) 2020; 6: 6.

73. Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis 2020; 7: ofaa016. [PubMed: 32099843]

Key messages

- The endemic mycoses cause disease in both immunocompetent and immunocompromised hosts.
- The geographical range of the endemic mycoses continues to expand, following their recognition in non-traditional regions.
- Several novel species have been recently described in the endemic mycoses.
- Advances in laboratory techniques and non-invasive testing have improved diagnostic test specificity and sensitivity.
- Radiographic imaging is generally warranted only if concern for infection at a particular site exists—routine radiography is not typically indicated.
- Treatment options continue to expand, and our understanding of agent selection as well as dose and duration of therapy continues to evolve.

Panel: How the guideline group worked

In January, 2018, experts were identified based on their publication activity in the field of the endemic mycoses in the previous 5 years, their involvement in patient management, and their distribution over world regions defined by the UN. Experts were invited to develop this guideline in February, 2018.

This guideline follows the structure and definitions of previous guidelines on invasive fungal infections, which are in accordance with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) and Appraisal of Guidelines for Research & Evaluation (AGREE) systems. The PICO (population, intervention, comparison, and outcome) approach is reflected by the tables listed in the appendix (p 7).

Both, diagnostic assays and treatment strategies might alter patient course, and are thus regarded as interventions. First, a population is defined; then the intention or objective is stated, followed by the intervention. For such logical sequence, strength of recommendation (SOR) and quality of evidence (QOE) are provided, followed by the references on which the recommendation is based. SOR and QOE are results of two independent evaluations, thus allowing a strong recommendation even in the absence of the highest quality evidence.

Search strings used were (“endemic mycoses” OR “endemic fungal infect*” OR Blastomyc* OR Coccidioid* OR Emmonsi* OR Emergomyc* OR Histoplasm* OR Paracoccidioid* OR Penicilliosis OR “Penicillium marneffei” OR Sporotrichosis OR Sporothr* OR Talaromyc* [All Fields]) AND (epidemiology OR outbreak OR treatment OR therapy OR diagnosis OR diagnostics) OR (case*[Title/Abstract] OR patient*[Title/Abstract] OR report[Title/Abstract]) AND (“2013/01/01”[Pratt]:“2017/12/31”[PDat])”.

From March to May, 2018, video conferences on the methodology were held, and a video tutorial was added in March, 2018. Assistance and supervision to the group were provided by the coordinators (GRT, TL, AC, ACP). Documents were shared among the authors on a password-protected OneDrive (Microsoft Corp, Redmond, WA, USA) repository, and were updated several times per day. Updates on PICO tables were written in red font; after spellcheck and formatting font colour was changed to blue for consideration by the group. Contents discussed and agreed on were changed to black font. Once all tables were finalised, a writing group, including all authors, contributed the first draft, which was circulated to all participants in February, 2020. Recommendations were consensus-based. If no consensus was found, majority vote was used.

In June, 2020, a 4-week public consultation phase ensued. Comments received were evaluated, and either dismissed or used to change the manuscript, resulting in a final author review in December, 2020. 37 scientific societies reviewed and endorsed the guidance document.



Figure 1: Geographical regions of the endemic mycoses (A–G)



Figure 2: Microscopic findings of endemic mycoses

(A) Grocott methenamine silver staining of *Blastomyces* spp yeast from a tissue sample with broad-based budding apparent in centre (400× magnification; courtesy of Dr Carol Kauffman). (B) Hematoxylin and eosin staining of *Coccidioides* spp spherule containing numerous endospores (40× magnification; courtesy of Dr Bridget Barker). (C) Silver staining shows yeast forms of *Histoplasma* spp (40× magnification; courtesy of Dr John Baddley). (D) Lactophenol cotton blue staining of a smear paracoccidioidomycosis (400× magnification; courtesy of Dr Flavio Telles). (E) Lactophenol cotton blue stain shows rosette-like clusters at the tips of the conidiophores, which are characteristic of *Sporothrix* spp (40× magnification; courtesy of Dr Flavio Telles). (F) Giemsa stain shows transverse septum (arrow) in a dividing yeast cell, which is characteristic of *Talaromyces marneffei* (60× magnification; courtesy of Dr Thuy Le).